3Stack WA, Mann SD, Roy AJ, Heath P, Sopwith M, Freeman J,Holmes G, Long R, Forbes A, Kamm MA. Randomised controlled trial of CDP571 antibody to tumour necrosis factoralpha in Crohn's disease. Lancet 1997;349:521-524. 被引量：1
4Vasiliauskas EA, Kam LY, Abreu-Martin MT, Hassard PV,Papadakis KA, Yang H, Zeldis JB, Targan SR. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. Gastroenterology 1999;117:1278-1287. 被引量：1
5Ehrenpreis ED, Kane SV, Cohen LB, Cohen RD, Hanauer SB.Thalidomide therapy for patients with refractory Crohn's disease:an open-label trial. Gastroenterology 1999;117:1271-1277. 被引量：1
6Facchini S, Candusso M, Martelossi S, Liubich M, Panfili E,Ventura A. Efficacy of long-term treatment with thalidomide in children and young adults with Crohn disease: preliminary results. J Pediatr Gastroenterol Nutr 2001;32:178-181. 被引量：1
7Bauditz J, Wedel S, Lochs H. Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease. Gut 2002;50:196-200. 被引量：1
8D'Haens G, Swijsen C, Noman M, Lemmens L, Ceuppens J,Agbahiwe H, Geboes K, Rutgeerts P. Etanercept in the treatment of active refractory Crohn's disease: a single-center pilot trial. Am J Gastroenterol 2001;96:2564-2568. 被引量：1
9Ghosh S, Goldin E, Gordon FH, Malchow HA, Rask-Madsen J,Rutgeerts P, Vyhnalek P, Zadorova Z, Palmer T, Donoghue S.Natalizumab for active Crohn's disease. N Engl J Med 2003;348:24-32. 被引量：1
10Gordon FH, Lai CW, Hamilton MI, Allison MC, Srivastava ED, Fouweather MG, Donoghue S, Greenlees C, Subhani J,Amlot PL, Pounder RE. A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease. Gastroenterology 2001;121:268-274. 被引量：1
4Collins P,Rhodes J. Ulcerative colitis:diagnosis and management[J].British Medical Journal,2006,(7563):340-343. 被引量：1
5Lok KH,Hung HG,Ng CH. Epidemiology and clinical characteristics of ulcerative colitis in Chinese population:experience from a single center in Hong Kong[J].Gastroenterologia Y Hepatologia,2008,(03):406-410. 被引量：1
6Vind I,Riis L,Jess T. Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County,2003-2005:a population-based study from the Danish Crohn colitis database[J].American Journal of Gastroenterology,2006,(06):1274-1282. 被引量：1
7Jiang L,Xia B,Li J. Risk factors for ulcerative colitis in a Chinese population:an age-matched and sex-matched case-control study[J].Clinics in Gastroenterology,2007,(03):280-284. 被引量：1
8Olsen I,Tollefsen S,Aagaard C. Isolation of mycobacterium avium subspecies paratuberculosis reactive CD4 T cells from intestinal biopsies of crohn's disease patients[J].PLoS One,2009,(05):e5641. 被引量：1
9Toyoda H,Wang SJ,Yang HY. Distinct associations of HLA class Ⅱ genes with inflammatory bowel disease[J].Gastroenterology,1993,(03):741-748. 被引量：1
10Masuda H,Nakamura Y,Tanaka T. Distinct relationship between HLA-DR genes and intractability of ulcerative colitis[J].American Journal of Gastroenterology,1994,(11):1957-1962. 被引量：1
